TIDMIDH
RNS Number : 5229Y
Immunodiagnostic Systems Hldgs PLC
04 September 2009
?
Immunodiagnostic Systems Holdings plc
Licensing agreement with Biosignatures Ltd
& Directorate Change
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading
producer of diagnostic testing kits for the clinical and research markets,
announces that it has agreed licence terms with Biosignatures
Limited ("Biosignatures") to use new Biomarkers associated with kidney disease
identified through Biosignatures' discovery programme.
Biosignatures, based in Newcastle upon Tyne, is a novel clinical diagnostic
company generating high performance diagnostic signatures of disease states
through its proprietary discovery platform. This proteomics-based technology
draws upon the extensive experience of the founders with Nonlinear Dynamics,
from which Biosignatures emerged.
The agreement plays to the strengths of both companies in accelerating the
discovery of new disease biomarkers and feeding these into the proven
immunoassay development machine that is IDS. The initial focus is to be kidney
diseasesand related conditions.
It is hoped that this will be the first of many deals between the two companies
as IDS continues the exploitation of its world leading IDS iSYS platform and
Biosignatures rolls out its world first discovery technology.
Roger Duggan, CEO of IDS, said: "We're very excited about this deal. The
enormous promise of the 'proteomics approach' to new biomarker discovery as
embraced by many heavyweight academic and biotech giants has largely
disappointed. We are particularly pleased to be working with a highly innovative
partner in Biosignatures who have an enlightened approach to proteomics based
upon extensive hard-headed commercial experience."
Directorate Change
Will Dracup, a non-executive director of IDS, is also Chief Executive of
Biosignatures. In the light of the commercial collaboration with IDS, he will
reluctantly step down from the IDS board with immediate effect.
The Board thanks Will for his valuable contribution whilst a Board member and
wishes him every success with his new endeavour.
The Board is actively seeking a replacement for Will and an announcement will be
made in due course.
ENDS
Enquiries:
+------------------------------------+------------------------------------+
| Immunodiagnostic Systems Holdings | Tel: 0191 519 0660 |
| Plc | |
+------------------------------------+------------------------------------+
| Roger Duggan, CEO | |
+------------------------------------+------------------------------------+
| Paul Hailes, Finance Director | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Brewin Dolphin Investment Banking | Tel: 0845 213 4730 |
+------------------------------------+------------------------------------+
| Andrew Emmott | |
| Sean Wyndham-Quin | |
+------------------------------------+------------------------------------+
| | |
+------------------------------------+------------------------------------+
| Walbrook PR Ltd | Tel: 020 7933 8787 |
+------------------------------------+------------------------------------+
| Paul McManus | Mob: 07980 541 893 |
+------------------------------------+------------------------------------+
| | paul.mcmanus@walbrookpr.com |
+------------------------------------+------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLJMRTMMBMBLL
|